Deutsch
A A A
Bereichsnavigation

Previous
RHÖN-KLINIKUM AG | 06/12/2014

Annual General Meeting of RHÖN-KLINIKUM AG on 12th June 2014 in Frankfurt / Main

Financial Figures for 2013

  • Number of treated patients rises by +4 percent to approx. 2.65 million
  • Revenue increases +5.2 percent and crosses the three billion mark for the first time
  • Net consolidated profit almost constant at € 90 million
  • Sales proceeds to be distributed by share buy-back of up to roughly € 1.67 billion
  • Dividend proposal of 25 cent per share

First Quarter 2014 Results

  • Financial figures significantly influenced by extraordinary effects
  • 567,137 patients treated
  • Revenues amount to € 629.5 million
  • EBITDA stands at € 1,488.0 million due to sales proceeds

RHÖN-KLINIKUM AG Looks Back on a Historic Business Year

"We experienced an extraordinary business year 2013 and are fundamentally different today in scope, content and demands from the RHÖN-KLINIKUM AG which presented itself at the last AGM. A once heterogeneous hospital group with 54 hospitals offering a wide range of primarily in-patient medical services is now going through a structured process of change to become an integrated healthcare group. On the basis of ten highly specialised hospitals with a close link to universities and research institutes, we will concentrate on innovative cutting-edge medical care and treatment of the highest quality. Patient well-being will continue to remain the main focus of our work in the future," the CEO, Dr. Dr. Martin Siebert, explained at the company's Annual General Meeting in Frankfurt today.

The process of fundamental change also significantly influenced the financial figures of the company both in the past financial year and also in the first quarter of 2014.

The financial statement for the first three months of the current financial year therefore includes two months with the full consolidation of the previous portfolio in its entirety as well as the month of March with an adjusted balance sheet showing the concluded sale transaction. Added to this are numerous primarily positive one-off effects as well as burdens which can generally be attributed to the transaction. Taking the above exceptional situation into account, 567,137 patients were treated in the hospitals of RHÖN-KLINIKUM AG in the first quarter of the current financial year. Revenues are at € 629.5 million while earnings before interest, taxes, depreciation and amortisation (EBITDA) amount to € 1,488.0 million.

In financial year 2013 a total of roughly 2.65 million patients were treated in the 54 RHÖN KLINIKUM AG hospitals which belonged to the corporate group last year – an increase of 3.9 %. The revenue of the entire corporate group grew by 5.2 % and with € 3.01 billion crossed the three billion mark for the first time. Due to considerable extraordinary burdens from the transaction earnings before interest, taxes, depreciation and amortisation was reduced by 5.7 %, now amounting to € 275.4 million. Net consolidated profit remained almost unchanged at € 90.0 million.

Proposal: Share Buy-Back and Dividend of 25 Cent per Share

The Board of Management and Supervisory Board proposed to this year's ordinary Annual General Meeting to distribute to the shareholders up to roughly € 1.67 billion from the proceeds of the transaction with Fresenius/HELIOS by way of share buy-back. The shares which are repurchased will be cancelled and the registered share capital reduced accordingly. The smaller corporate size will thus be taken into account. The share buy back also enables shareholders to exit the company in a manner that limits the impact on the share price.

Furthermore the Board of Management and Supervisory Board proposed to the AGM the distribution of a dividend totalling roughly € 34.6 million or € 0.25 per share as in the previous year.

Positive Development at the Hospitals

Siebert explained that all five sites of the company were developing in a positive manner. Major projects are the planned reconstruction of the hospital site in Bad Neustadt by 2018 and taking the particle therapy unit in Marburg into service in the foreseeable future after all the parties concerned were able to define the key points for long-term operation. The contractual texts required here are currently being finalised. We shall be able to commence treating patients next year already with this unique unit providing cancer therapy.

The consolidation of the largest component of our portfolio – the university hospitals in Giessen and Marburg – is progressing step by step, says Siebert. "Our dedicated work in a complicated environment which is also extremely sensitive both publicly and politically is bearing fruit. After we recorded a loss of € 8.6 million in 2012, we were able to achieve a positive annual result of approx. € 2 million in 2013." After a long period of fundamental criticism of the privatisation a more constructive and objective tone is now increasingly taking hold. "That also makes it much easier for our employees in Giessen and Marburg to identify with their hospital."

RHÖN-KLINIKUM AG Well-Equipped for a Heterogeneous Market Environment

Siebert pointed out that RHÖN-KLINIKUM AG still works in a regulated market environment with structural deficiencies and there are therefore regular political efforts to reform the hospital sector. The cost pressure will noticeably increase due to the demographic development despite the positive perspectives of growth in the long-term.

"We shall consider all relevant scenarios in our market environment, assess the consequences for our company and make the corresponding decisions in order to maintain a sustainable and viable position for the future," Siebert explained.

"As an independent hospital group we shall remain assertive and make the most of business opportunities. Our brand and mission statement – innovation and high quality treatment – makes us unique in the market. I am convinced that we have the best prerequisites for our new constellation to be able to write a further chapter of success in forward-looking healthcare in our corporate history," Siebert went on to say. The network medicine project whose creation has already been initiated will also make a noticeable contribution.